Skip to main content
Fig. 2 | BMC Pharmacology and Toxicology

Fig. 2

From: Rituximab impedes natural killer cell function in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients: A pilot in vitro investigation

Fig. 2

Natural killer cell cytotoxicity. Bar graph plots representing in vitro assessment of NK (cytotoxic activity) of tumour-cell lines K562 in CFS/ME (n = 8) and NFC (n = 9). Lytic activity represented by percentage lysis of target cells on the y-axis. (a). Represents data at 12.5:1 effector target ratio. (b). Represents data at 6.25:1 effector target ratio. Data presented as mean ± standard deviation. * refers to significant difference where p < 0.05 and ** refers to significant difference where p < 0.01. Abbreviations: NK, natural killer; ME, myalgic encephalomyelitis; CFS, chronic fatigue syndrome; NFC, non-fatigued control; RTX, Rituximab; NK, natural killer

Back to article page

BMC Pharmacology and Toxicology

ISSN: 2050-6511

Contact us